| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
159,210,000 |
| Market
Cap: |
1.10(B) |
| Last
Volume: |
2,204,422 |
Avg
Vol: |
2,198,459 |
| 52
Week Range: |
$2.7 - $7.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Markbreiter Michael |
Director |
– • – |
2010-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
12,000 |
|
- |
|
| Mengler Christopher |
President, Global Pharm. Div. |
• – – |
2010-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
57,706 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2010-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
46,000 |
340,793 |
|
- |
|
| Chao Allen |
Director |
– • – |
2010-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,800 |
39,095 |
|
- |
|
| Koch Arthur A Jr |
SVP, Finance, and CFO |
• – – |
2010-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
13,000 |
102,966 |
|
- |
|
| Burr Robert L |
Director |
– • – |
2010-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
45,150 |
|
- |
|
| Fleming Nigel |
Director |
– • – |
2010-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
28,000 |
|
- |
|
| Hildenbrand Charles V |
SVP, Operations |
• – – |
2010-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
38,524 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2010-05-20 |
4 |
D |
$19.65 |
$279,698 |
D/D |
(14,234) |
294,793 |
|
- |
|
| Koch Arthur A Jr |
SVP, Finance, and CFO |
• – – |
2010-05-20 |
4 |
D |
$19.65 |
$177,518 |
D/D |
(9,034) |
89,966 |
|
- |
|
| Markbreiter Michael |
Director |
– • – |
2010-05-20 |
4 |
S |
$19.80 |
$377,250 |
D/D |
(19,000) |
8,000 |
|
- |
|
| Markbreiter Michael |
Director |
– • – |
2010-05-20 |
4 |
OE |
$6.55 |
$98,250 |
D/D |
15,000 |
27,000 |
|
- |
|
| Nestor Michael |
President, Impax Pharm. Div. |
• – – |
2010-05-20 |
4 |
D |
$19.65 |
$23,442 |
D/D |
(1,193) |
41,701 |
|
- |
|
| Hildenbrand Charles V |
SVP, Operations |
• – – |
2010-05-20 |
4 |
D |
$19.65 |
$48,653 |
D/D |
(2,476) |
29,524 |
|
- |
|
| Fleming Nigel |
Director |
– • – |
2010-05-17 |
4 |
S |
$19.50 |
$156,000 |
D/D |
(8,000) |
24,000 |
|
- |
|
| Fleming Nigel |
Director |
– • – |
2010-05-17 |
4 |
OE |
$5.63 |
$45,000 |
D/D |
8,000 |
32,000 |
|
- |
|
| Benet Leslie Z |
Director |
– • – |
2010-05-07 |
4 |
S |
$17.10 |
$205,189 |
D/D |
(12,000) |
3,000 |
|
- |
|
| Benet Leslie Z |
Director |
– • – |
2010-05-07 |
4 |
OE |
$10.19 |
$122,280 |
D/D |
12,000 |
15,000 |
|
- |
|
| Chao Allen |
Director |
– • – |
2010-04-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
256,000 |
|
- |
|
| Mengler Christopher |
President, Global Pharm. Div. |
• – – |
2010-03-05 |
4 |
D |
$16.48 |
$37,805 |
D/D |
(2,294) |
44,706 |
|
- |
|
| Markbreiter Michael |
Director |
– • – |
2010-03-02 |
4 |
S |
$15.38 |
$230,700 |
D/D |
(15,000) |
12,000 |
|
- |
|
| Markbreiter Michael |
Director |
– • – |
2010-03-02 |
4 |
OE |
$7.10 |
$114,000 |
D/D |
15,000 |
27,000 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2010-02-13 |
4 |
D |
$13.91 |
$14,077 |
I/I |
(1,012) |
24,388 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2009-12-16 |
4 |
GA |
$0.00 |
$0 |
D/D |
2,235 |
309,027 |
|
- |
|
| Hsu Larry |
President and CEO |
• • – |
2009-12-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,235 |
25,400 |
|
- |
|
531 Records found
|
|
Page 17 of 22 |
|
|
0.11 (1.57%) 
